Samuel M Moskowitz

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Antimicrob Chemother 65:1416-23. 2010
  2. pmc Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 46:184-92. 2011
  3. pmc PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1019-30. 2012
  4. pmc Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis
    Robert K Ernst
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 196:1088-92. 2007
  5. pmc PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients
    Amanda K Miller
    Department of Pediatrics, University of Washington, Seattle, Washington 02114, USA
    Antimicrob Agents Chemother 55:5761-9. 2011
  6. pmc Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems
    Alina D Gutu
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 57:2204-15. 2013
  7. ncbi request reprint Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Antimicrob Chemother 56:879-86. 2005
  8. pmc The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway
    Robert K Ernst
    Department of Medicine, University of Washington, HSB T 293, Box 357710, 1959 Pacific Street N E, Seattle, WA 98195, USA
    J Bacteriol 188:191-201. 2006
  9. pmc Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, and Division of Pulmonary Medicine, Children s Hospital and Regional Medical Center, Seattle, USA
    J Clin Microbiol 42:1915-22. 2004
  10. pmc The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection
    Samuel M Moskowitz
    Simches Research Center, Massachusetts General Hospital, 185 Cambridge Street, CPZN 3 830, Boston, MA, 02114, USA
    Subcell Biochem 53:241-53. 2010

Research Grants

  1. Polymyxin-resistant Pseudomonas in CF Lung Infection
    Samuel M Moskowitz; Fiscal Year: 2010
  2. Polymyxin-resistant Pseudomonas in CF Lung Infection
    Samuel M Moskowitz; Fiscal Year: 2009

Collaborators

Detail Information

Publications19

  1. pmc Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Antimicrob Chemother 65:1416-23. 2010
    ..To assess the reliability of four standard testing methods, this pilot study used a challenge set that included polymyxin-resistant isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia...
  2. pmc Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 46:184-92. 2011
    ..In cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing would more accurately reflect the susceptibilities of bacteria infecting CF airways...
  3. pmc PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 56:1019-30. 2012
    ..These results indicate that pmrB gain-of-function mutations can contribute to high-level polymyxin resistance in clinical strains of P. aeruginosa...
  4. pmc Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis
    Robert K Ernst
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 196:1088-92. 2007
    ..None of the isolates from the environment or from patients with other conditions displayed these modifications. These results indicate that unique lipid A modifications occur in clinical P. aeruginosa CF isolates...
  5. pmc PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients
    Amanda K Miller
    Department of Pediatrics, University of Washington, Seattle, Washington 02114, USA
    Antimicrob Agents Chemother 55:5761-9. 2011
    ..These results indicate that phoQ loss-of-function mutations can contribute to high-level polymyxin resistance in clinical strains of P. aeruginosa...
  6. pmc Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems
    Alina D Gutu
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 57:2204-15. 2013
    ....
  7. ncbi request reprint Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Antimicrob Chemother 56:879-86. 2005
    ..As a prelude to a clinical trial of biofilm susceptibility testing in CF, simulated antibiotic regimens based on either biofilm or conventional susceptibility testing of CF patient isolates were compared...
  8. pmc The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway
    Robert K Ernst
    Department of Medicine, University of Washington, HSB T 293, Box 357710, 1959 Pacific Street N E, Seattle, WA 98195, USA
    J Bacteriol 188:191-201. 2006
    ..Finally, deacylated lipid A species were not observed in some clinical P. aeruginosa isolates from patients with severe pulmonary disease, suggesting that loss of PagL function can occur during long-term adaptation to the CF airway...
  9. pmc Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, and Division of Pulmonary Medicine, Children s Hospital and Regional Medical Center, Seattle, USA
    J Clin Microbiol 42:1915-22. 2004
    ....
  10. pmc The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection
    Samuel M Moskowitz
    Simches Research Center, Massachusetts General Hospital, 185 Cambridge Street, CPZN 3 830, Boston, MA, 02114, USA
    Subcell Biochem 53:241-53. 2010
    ..These lipid A modifications represent an essential aspect of PA adaptation to the CF airway...
  11. ncbi request reprint Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness
    Lindsey N Johnson
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    Pediatr Infect Dis J 23:881-2. 2004
    ..We describe a case of Pandoraea bacteremia in a 16-year-old cystic fibrosis patient associated with clinical disease, suggesting that this organism should be considered a true pathogen in susceptible patients...
  12. pmc Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195 7740, USA
    Genet Med 10:851-68. 2008
    ..Widespread implementation of newborn screening programs among populations with significant cystic fibrosis mutation carrier frequencies is expected to result in increasing demands on genetic counseling resources...
  13. ncbi request reprint Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4
    Robert K Ernst
    Department of Medicine, HSB K 155, Box 357710, University of Washington, Seattle, WA 98195, USA
    J Endotoxin Res 9:395-400. 2003
    ..P. aeruginosa adaptation to the human airway may, therefore, play a fundamental role in the progressive lung damage associated with cystic fibrosis...
  14. pmc Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
    Eric E Smith
    Genome Center, Program in Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:8487-92. 2006
    ..aeruginosa strains present in advanced CF infections differ systematically from those of "wild-type" P. aeruginosa and that these differences may offer new opportunities for treatment of this chronic disease...
  15. doi request reprint Shifting patterns of inhaled antibiotic use in cystic fibrosis
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195 7740, USA
    Pediatr Pulmonol 43:874-81. 2008
    ..Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients...
  16. pmc PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195, USA
    J Bacteriol 186:575-9. 2004
    ..Thus, P. aeruginosa possesses a mechanism that induces resistance to cationic antimicrobial peptides in response to environmental conditions...
  17. pmc Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos
    Mark K Brannon
    Department of Pediatrics, University of Washington, Seattle, WA, USA
    Cell Microbiol 11:755-68. 2009
    ..aeruginosa pathogenesis in conditions associated with neutropenia or impaired phagocyte function...
  18. pmc Mechanisms of bacterial virulence in pulmonary infections
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Curr Opin Crit Care 16:8-12. 2010
    ..To consider the relevance to severe human lung infections of recently discovered virulence mechanisms of Staphylococcus aureus and Francisella tularensis...
  19. ncbi request reprint Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine and Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
    Pediatr Radiol 35:739-57. 2005
    ..In this review, perspectives on the genetics and microbiology of CF provide a context for understanding the increasing importance of HRCT and other imaging techniques in assessing CF therapies...

Research Grants2

  1. Polymyxin-resistant Pseudomonas in CF Lung Infection
    Samuel M Moskowitz; Fiscal Year: 2010
    ..An interdisciplinary study of polymyxin resistant Pseudomonas from patients with cystic fibrosis is proposed to pinpoint the bacterial genes responsible for this resistance, so that management strategies may be devised to overcome it. ..
  2. Polymyxin-resistant Pseudomonas in CF Lung Infection
    Samuel M Moskowitz; Fiscal Year: 2009
    ..An interdisciplinary study of polymyxin resistant Pseudomonas from patients with cystic fibrosis is proposed to pinpoint the bacterial genes responsible for this resistance, so that management strategies may be devised to overcome it. ..